Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

The United Bio-Technology (Hengqin) Co., Ltd.

ClinicalTrials.gov lists The United Bio-Technology (Hengqin) Co., Ltd. as lead sponsor of 11 trials. It has 30 active development programs and 4 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Disease areas Disease areas 6 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Active development programs Active development programs 30 Approved assets Approved assets 4 Sponsor delivery record Sponsor delivery record 1 Latest dated events Latest dated events 11 Biomarker capability evidence Biomarker capability evidence 98 Disease areas Disease areas 6 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Active development programs Active development programs 30 Approved assets Approved assets 4 Sponsor delivery record Sponsor delivery record 1 Latest dated events Latest dated events 11 Biomarker capability evidence Biomarker capability evidence 98

Rows recorded per section (log scale)

17 sections measured, none recorded

This page covers The United Bio-Technology (Hengqin) Co., Ltd.: 11 lead-sponsored trials and 0 legal-entity registrations.

Get the The United Bio-Technology (Hengqin) Co., Ltd. report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (6)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Obesity 6
Diabetes Mellitus 4
Diabetes Mellitus, Type 2 4
Sleep Apnea Syndromes 2
Sleep Apnea, Obstructive 2

Showing 5 of 6 disease areas.

Start your 14-day trial Email me all 6 disease areas as a PDF

Trials by start year as sponsor or collaborator (2)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 7
2025 4

No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 29 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

Active development programs (30)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
UBT251 Obesity Phase 3 4
UBT251 Sleep Apnea, Obstructive Phase 3 2
UBT251 Sleep Apnea Syndromes Phase 3 2
Semaglutide Injection Diabetes Mellitus Phase 3 2
Semaglutide Injection Diabetes Mellitus, Type 2 Phase 3 2

Showing 5 of 30 active programs.

Start your 14-day trial Email me all 30 active programs as a PDF

Approved assets (4)

Shown in this order: max phase first.

Approved assets
Drug Trials
Sodium warfarin 1
Digoxin 1
METFORMIN 1
ATORVASTATIN 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
not enough data 2 of 2 on time (n=2)

Latest dated events (11)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-10-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-18 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-07 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-07 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-07-31 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Showing 5 of 11 events.

Start your 14-day trial Email me all 11 events as a PDF

Biomarker capability evidence (98)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ACE Trial sponsor Named in trial inclusion criteria
CBR1 Trial sponsor Named in trial inclusion criteria
CORIN Trial sponsor Named in trial inclusion criteria
CRNKL1 Trial sponsor Named in trial inclusion criteria
NR3C2 Trial sponsor Named in trial inclusion criteria

Showing 5 of 98 evidence rows.

Start your 14-day trial Email me the first 50 evidence rows as a PDF

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, journals published in, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.